ARTICLE | Clinical News
Zubsolv buprenorphine/naloxone regulatory update
October 10, 2016 7:00 AM UTC
Orexo and Mundipharma submitted an MAA to EMA for Zubsolv buprenorphine/naloxone to treat opioid dependence. The sublingual tablet of buprenorphine and naloxone is marketed in the U.S. for maintenance...